| WARF: P04067US |  |
| 2-Methylene-19-Nor--20(S)-25-Methyl-1Alpha-Hydroxycalciferol and its Uses |
| INVENTORS | • | Hector DeLuca, Pawel Grzywacz |
OVERVIEW
Vitamin D (1,25-dihydroxyvitamin D3) is a highly potent regulator of calcium
homeostasis and plays a role in cellular differentiation. The 19-nor-vitamin D
compounds, a recently discovered class of vitamin D analogs, show a selective
activity profile with high potency in inducing cellular differentiation, making
them potentially useful for treating various disorders. This invention
provides a vitamin D analog,
2-methylene-19-nor-20(S)-25-methyl-1alpha-hydroxycalciferol. This
compound is characterized by relatively high intestinal calcium transport
activity and relatively low bone calcium mobilization activity as compared to
1,25-dihydroxyvitamin D3, making it highly specific in its calcemic activity.
This compound also exhibits high cell differentiation activity.
KEY BENEFITS
- Potentially useful as an anti-cancer agent, particularly against leukemia, colon, breast, and prostate cancers
- Promising therapeutic agent for treating diseases where bone formation is desired, such as osteoporosis, osteomalacia, and renal osteodystrophy
- May be useful for improving bone fracture healing and bone grafts
- Especially useful for treating immune disorders including multiple sclerosis, lupus, diabetes mellitus, host-versus-graft reaction, and organ transplant rejection
- Prospective treatment for inflammatory diseases such as rheumatoid arthritis, asthma, and inflammatory bowel diseases
- May be useful for treating skin conditions such as psoriasis, dermatitis, eczema, keratosis, wrinkles, slack skin, dry skin, and insufficient sebum secretion
- Potential treatment for other disorders including acne, alopecia, and hypertension
ADDITIONAL INFORMATION
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Vitamin D
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
